Solara Active Pharma Sciences Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/h429erllyeor0wibmoxzdcua.pdf

Key Takeaways


The Ibuprofen Problem

Arun Kumar: "Clearly, for the generic market, we're not competitive. We sell, our gross margin at 21% is in spite of us selling the product at least 15% to 17% greater than our competition because we sell to big pharma."

Strategic Review & Corporate Actions

Arun Kumar: "So although at that time when we announced it, we thought it was the right thing to do, on further reflection, we think there's more value to retain everything in one house."

The Growth API Business


Vizag Plant & Capacity Reconfiguration


CDMO & OneSource


Financial Performance

MetricQ3 FY26QoQ ChangeCommentary
RevenueINR346 crores▲ 10%Driven by growth business momentum; ibuprofen remained a drag
Gross Margin47%▼ 386 bpsOne of the lowest in recent quarters; entirely ibuprofen-driven
EBITDAINR37 crores (~11% margin)▲ 6%Marginal growth, impacted by lower gross margins
OpexFlat QoQ▬Considering cyclical nature of some Q3 expenses
One-time impactINR6.7 crores adverse—Change in labor wage code effective 21 Nov, increased gratuity and leave encashment liability
DebtReduced by INR146 crores▼ 19%INR113 crores from rights issue call money, INR33 crores from operational cash flows

Guidance & Commitments

CommitmentSpecificsTimeline
Ibuprofen strategic review outcomeResults of external advisor analysis disclosed with clear directionQ4 results (end of April)
Ibuprofen carve-out dataRevenue and margin data for ibuprofen API providedQ4 results
Debt reductionDebt to sub-INR500 crores levelsBy May '26, post final rights issue call
OneSource product launchSpecific CDMO product launch following approvalFY '27 financial year
Growth API gross margin55-56% range to guideNext few years

Key Metrics

MetricQ3 FY26
Revenue₹346 cr, +10% QoQ and roughly +15% YoY
Gross margin47%, down 386 bps QoQ; lowest in recent quarters
EBITDA₹37 cr, +6% QoQ
EBITDA margin~11%
Developed markets revenue share75% of overall sales
One-time labor code impact₹6.7 cr adverse, from gratuity and leave encashment liability
Net debt reduction (9M FY26)~₹146 cr (adjusted for forex), down ~19%; ₹113 cr from rights issue call, ₹33 cr from operational cash flows
Projected net debt by May '26Sub-₹500 cr, post receipt of final rights call money
Non-ibuprofen business gross margin56%
Non-ibuprofen business EBITDA margin25%
Ibuprofen plain API gross margin21%, despite selling at 15–17% premium to competition
Ibuprofen capacity utilization~3,000 tons, against combined capacity of 10,000–12,000 tons
Growth API capacity utilizationA little over 70%
Consolidated gross margin decline (YoY)~800 bps drop between last year and this year